| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | POLR1D |
| Uniprot No | P0DPB6 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-133aa |
| 氨基酸序列 | MEEDQELERKISGLKTSMAEGERKTALEMVQAAGTDRHCVTFVLHEEDHTLGNSLRYMIMKNPEVEFCGYTTTHPSESKINLRIQTRGTLPAVEPFQRGLNELMNVCQHVLDKFEASIKDYKDQKASRNESTF |
| 预测分子量 | 42.2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于POLR1D重组蛋白的3篇参考文献(基于公开信息模拟整理，非真实文献)：
1. **文献名称**：*Structural insights into POLR1D subunit in RNA polymerase III complex*
**作者**：Li X, et al.
**摘要**：该研究解析了POLR1D重组蛋白在RNA聚合酶III中的结构，揭示了其与POLR1C亚基的相互作用机制，为理解RNA聚合酶III组装异常相关疾病的分子基础提供了依据。
2. **文献名称**：*POLR1D mutations impair recombinant protein stability and ribosome biogenesis*
**作者**：Garcia MG, et al.
**摘要**：通过体外重组表达POLR1D突变体蛋白，证明其稳定性下降导致RNA聚合酶I功能受损，阐明了POLR1D突变引发颅面发育障碍的分子路径。
3. **文献名称**：*Recombinant POLR1D as a biomarker for Treacher Collins syndrome*
**作者**：Thompson R, et al.
**摘要**：开发了重组POLR1D蛋白检测技术，发现其表达水平与Treacher Collins综合征患者表型严重程度相关，为临床诊断提供了新方法。
注：以上文献为示例性内容，实际研究中请通过PubMed或Web of Science等平台检索真实文献。
POLR1D (RNA Polymerase I and III Subunit D) is a critical component of the RNA polymerase I and III complexes, which are essential for synthesizing ribosomal RNA (rRNA) and small RNAs, including transfer RNAs (tRNAs) and 5S rRNA. These RNA molecules play fundamental roles in ribosome biogenesis, protein synthesis, and cellular homeostasis. The POLR1D gene encodes a shared subunit that contributes to the structural integrity and enzymatic activity of both RNA polymerase I (Pol I) and III (Pol III). Dysregulation of POLR1D has been linked to developmental disorders and cancer. For instance, heterozygous mutations in POLR1D are associated with Treacher Collins syndrome, a craniofacial disorder characterized by abnormal head and face development, as well as autosomal dominant hearing loss. In cancer, POLR1D has been implicated as both a potential oncogene and tumor suppressor, depending on the context, with altered expression observed in various malignancies.
Recombinant POLR1D protein is engineered for functional studies to elucidate its role in transcription, ribosome assembly, and disease mechanisms. Produced using heterologous expression systems (e.g., E. coli or mammalian cells), the recombinant protein retains the ability to integrate into Pol I/III complexes, enabling researchers to investigate its interactions with other subunits, DNA, or regulatory factors. Studies using recombinant POLR1D have also explored how pathogenic mutations disrupt RNA polymerase assembly or activity, providing insights into molecular pathways underlying related disorders. Additionally, this tool aids in screening therapeutic compounds targeting Pol I/III activity, particularly in cancers reliant on hyperactive rRNA synthesis. Overall, POLR1D recombinant proteins serve as vital reagents for dissecting the molecular basis of transcription-linked diseases and developing targeted interventions.
×
